Compare Stocks: NERV, OCS, OVID, and SPRY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NERV Minerva Neurosciences	$2.40 +0.4%	$3.77	$2.24 ▼ $8.80	$114.12M	-0.1	118,860 shs	121,144 shs
OCS Oculis	$8.09 +2.8%	$10.35	$7.11 ▼ $34.47	$456.34M	0.62	345,810 shs	427,572 shs
OVID Ovid Therapeutics	$2.37 -4.0%	$2.60	$1.18 ▼ $3.11	$482.39M	0.22	1.72 million shs	1.18 million shs
SPRY ARS Pharmaceuticals	$4.32 +3.3%	$4.84	$3.81 ▼ $13.15	$415.69M	0.85	1.48 million shs	1.79 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NERV Minerva Neurosciences	+0.42%	-0.83%	-37.01%	-40.59%	-55.39%
OCS Oculis	+2.80%	+9.32%	-24.46%	-27.31%	-61.84%
OVID Ovid Therapeutics	-4.05%	+4.87%	-14.13%	+1.72%	+47.20%
SPRY ARS Pharmaceuticals	+3.35%	+6.14%	-3.57%	-27.27%	-55.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NERV Minerva Neurosciences	$2.40 +0.4%	$3.77	$2.24 ▼ $8.80	$114.12M	-0.1	118,860 shs	121,144 shs
OCS Oculis	$8.09 +2.8%	$10.35	$7.11 ▼ $34.47	$456.34M	0.62	345,810 shs	427,572 shs
OVID Ovid Therapeutics	$2.37 -4.0%	$2.60	$1.18 ▼ $3.11	$482.39M	0.22	1.72 million shs	1.18 million shs
SPRY ARS Pharmaceuticals	$4.32 +3.3%	$4.84	$3.81 ▼ $13.15	$415.69M	0.85	1.48 million shs	1.79 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NERV Minerva Neurosciences	+0.42%	-0.83%	-37.01%	-40.59%	-55.39%
OCS Oculis	+2.80%	+9.32%	-24.46%	-27.31%	-61.84%
OVID Ovid Therapeutics	-4.05%	+4.87%	-14.13%	+1.72%	+47.20%
SPRY ARS Pharmaceuticals	+3.35%	+6.14%	-3.57%	-27.27%	-55.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NERV Minerva Neurosciences	2.00	Hold	$10.33	330.56% Upside
OCS Oculis	2.80	Moderate Buy	$39.44	387.57% Upside
OVID Ovid Therapeutics	2.92	Moderate Buy	$6.00	153.16% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$25.00	478.70% Upside

Current Analyst Ratings Breakdown

Latest NERV, OCS, OVID, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	OCS Oculis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	OVID Ovid Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	OVID Ovid Therapeutics	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$5.00
10/15/2026	OVID Ovid Therapeutics	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$5.00
10/9/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/9/2026	OVID Ovid Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight
10/6/2026	OVID Ovid Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$7.00
10/5/2026	OVID Ovid Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$7.00
9/21/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/18/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$26.00 ➝ $39.00

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A
OCS Oculis	$1.45M	323.49	N/A	N/A	$4.08 per share	1.98
OVID Ovid Therapeutics	$7.25M	63.84	N/A	N/A	$1.00 per share	2.37
SPRY ARS Pharmaceuticals	$84.28M	5.10	N/A	N/A	$1.16 per share	3.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
OCS Oculis	-$119.44M	-$1.74	N/A	N/A	N/A	-6,777.18%	-42.61%	-35.23%	11/5/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.31	N/A	N/A	N/A	N/A	-23.64%	-20.52%	11/11/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)

Latest NERV, OCS, OVID, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	OVID Ovid Therapeutics	-$0.08	N/A	N/A	N/A	$0.03 million	N/A
11/9/2026	Q3 2026	SPRY ARS Pharmaceuticals	-$0.34	N/A	N/A	N/A	$41.99 million	N/A
11/5/2026	Q3 2026	OCS Oculis	-$0.49	N/A	N/A	N/A	$0.25 million	N/A
11/4/2026	Q3 2026	NERV Minerva Neurosciences	-$0.14	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	OVID Ovid Therapeutics	-$0.1150	-$0.08	+$0.0350	-$0.08	$0.02 million	$0.73 million
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A
8/6/2026	Q2 2026	OCS Oculis	-$0.48	-$0.20	+$0.28	-$0.20	$0.22 million	$0.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NERV Minerva Neurosciences	N/A	20.15	20.14
OCS Oculis	0.01	8.35	8.35
OVID Ovid Therapeutics	0.05	12.39	12.39
SPRY ARS Pharmaceuticals	13.72	3.48	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NERV Minerva Neurosciences	34.56%
OCS Oculis	22.30%
OVID Ovid Therapeutics	72.24%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
NERV Minerva Neurosciences	1.70%
OCS Oculis	N/A
OVID Ovid Therapeutics	7.00%
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NERV Minerva Neurosciences	7	47.75 million	46.94 million	Optionable
OCS Oculis	60	57.98 million	N/A	Optionable
OVID Ovid Therapeutics	23	195.30 million	181.63 million	Optionable
SPRY ARS Pharmaceuticals	200	99.45 million	65.83 million	Optionable

NERV, OCS, OVID, and SPRY Headlines

Recent News About These Companies

Head-To-Head Analysis: Bausch Health Cos (NYSE:BHC) versus ARS Pharmaceuticals (NASDAQ:SPRY)

October 19, 2026 | americanbankingnews.com

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 5, 2026 | tmcnet.com

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY

October 5, 2026 | prnewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

October 5, 2026 | prnewswire.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

October 4, 2026 | newsfilecorp.comN

SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 4, 2026 | newsfilecorp.comN

SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 3, 2026 | newsfilecorp.comN

ARS PHARMACEUTICALS DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

October 3, 2026 | newsfilecorp.comN

ARS Pharmaceuticals Officer Eric Karas Files Form 144 to Sell 100,000 Shares on NASDAQ

October 2, 2026 | kalkinemedia.comK

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

October 2, 2026 | prnewswire.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY

October 2, 2026 | globenewswire.com

ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role

October 2, 2026 | globenewswire.com

Kaplan Fox Class Action Reminder: ARS Pharmaceuticals Inc. (SPRY) Lead Plaintiff Deadline is October 5, 2026

October 1, 2026 | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

October 1, 2026 | globenewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

October 1, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

October 1, 2026 | prnewswire.com

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 1, 2026 | prnewswire.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $25.00

October 1, 2026 | marketbeat.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

September 30, 2026 | newsfilecorp.comN

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

September 30, 2026 | prnewswire.com

ARS Pharmaceuticals, Inc. (SPRY)

September 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NERV, OCS, OVID, and SPRY Company Descriptions

Minerva Neurosciences NASDAQ:NERV

$2.40 +0.01 (+0.42%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$2.40 0.00 (0.00%)

As of 10/22/2026 07:30 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Oculis NASDAQ:OCS

$8.09 +0.22 (+2.80%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$8.22 +0.13 (+1.55%)

As of 04:12 AM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Ovid Therapeutics NASDAQ:OVID

$2.37 -0.10 (-4.05%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$2.35 -0.02 (-0.84%)

As of 05:27 AM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

ARS Pharmaceuticals NASDAQ:SPRY

$4.32 +0.14 (+3.35%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$4.30 -0.03 (-0.58%)

As of 05:13 AM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, OCS, OVID, and SPRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, OCS, OVID, and SPRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, OCS, OVID, and SPRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NERV, OCS, OVID, and SPRY Company Descriptions

Minerva Neurosciences NASDAQ:NERV

Oculis NASDAQ:OCS

Ovid Therapeutics NASDAQ:OVID

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, OCS, OVID, and SPRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, OCS, OVID, and SPRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, OCS, OVID, and SPRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NERV, OCS, OVID, and SPRY Company Descriptions

Minerva Neurosciences NASDAQ:NERV

Oculis NASDAQ:OCS

Ovid Therapeutics NASDAQ:OVID

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools